169 related articles for article (PubMed ID: 19672256)
41. Soluble urokinase-type plasminogen activator receptor and ferritin concentration in patients with advanced alimentary tract carcinoma. Relationship to localization, surgical treatment and the stage of the disease--preliminary report.
Usnarska-Zubkiewicz L; Strutyńska-Karpińska M; Zubkiewicz-Kucharska A; Zarębski P; Grabowski K
Adv Clin Exp Med; 2014; 23(6):959-67. PubMed ID: 25618124
[TBL] [Abstract][Full Text] [Related]
42. [Dynamic changes in plasma levels of urokinase type plasminogen activator and urokinase type plasminogen activator receptor in patients with systemic inflammatory response syndrome].
Wu XL; Yu L; Long D; Yang JH; Zhang YC; Geng F
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2011 Aug; 23(8):478-81. PubMed ID: 21878172
[TBL] [Abstract][Full Text] [Related]
43. The liberated domain I of urokinase plasminogen activator receptor--a new tumour marker in small cell lung cancer.
Almasi CE; Drivsholm L; Pappot H; Høyer-Hansen G; Christensen IJ
APMIS; 2013 Mar; 121(3):189-96. PubMed ID: 23030781
[TBL] [Abstract][Full Text] [Related]
44. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
[TBL] [Abstract][Full Text] [Related]
45. Urokinase-type plasminogen activator receptor (uPAR) assessed by liquid biopsies and PET/CT for prognostication in head and neck cancer patients.
Risør LM; Binderup T; Fosbøl MØ; Andersen KF; Loft A; Friborg J; Kjaer A
Sci Rep; 2022 Nov; 12(1):19126. PubMed ID: 36352036
[TBL] [Abstract][Full Text] [Related]
46. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
J Acquir Immune Defic Syndr; 2005 May; 39(1):23-31. PubMed ID: 15851910
[TBL] [Abstract][Full Text] [Related]
47. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
[TBL] [Abstract][Full Text] [Related]
48. Preoperative Levels of the Soluble Urokinase-Type Plasminogen Activator Receptor as Predictor for New Episodes of Atrial Fibrillation After Vascular Surgery.
Lazarević M; Golubović M; Milić D; Stanojević D; Kostić T; Đorđević M; Marjanović V; Perić V
Vasc Endovascular Surg; 2021 Jul; 55(5):461-466. PubMed ID: 33622185
[TBL] [Abstract][Full Text] [Related]
49. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.
Sörensen NA; Nikorowitsch J; Neumann JT; Rübsamen N; Goßling A; Hartikainen TS; Blankenberg S; Westermann D; Zeller T; Karakas M
Clin Res Cardiol; 2019 Dec; 108(12):1386-1393. PubMed ID: 30989318
[TBL] [Abstract][Full Text] [Related]
50. Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Piironen T; Haese A; Huland H; Steuber T; Christensen IJ; Brünner N; Danø K; Høyer-Hansen G; Lilja H
Clin Chem; 2006 May; 52(5):838-44. PubMed ID: 16543389
[TBL] [Abstract][Full Text] [Related]
51. Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.
Lippert S; Berg KD; Høyer-Hansen G; Lund IK; Iversen P; Christensen IJ; Brasso K; Røder MA
Biomark Med; 2016; 10(2):209-16. PubMed ID: 26764285
[TBL] [Abstract][Full Text] [Related]
52. Involvement of urokinase receptor in the cross-talk between human hematopoietic stem cells and bone marrow microenvironment.
Selleri C; Montuori N; Salvati A; Serio B; Pesapane A; Ricci P; Gorrasi A; Li Santi A; Hoyer-Hansen G; Ragno P
Oncotarget; 2016 Sep; 7(37):60206-60217. PubMed ID: 27517491
[TBL] [Abstract][Full Text] [Related]
53. Specific immunoassays for detection of intact and cleaved forms of the urokinase receptor.
Piironen T; Laursen B; Pass J; List K; Gårdsvoll H; Ploug M; Danø K; Høyer-Hansen G
Clin Chem; 2004 Nov; 50(11):2059-68. PubMed ID: 15345662
[TBL] [Abstract][Full Text] [Related]
54. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
55. Diagnostic significance of measurement of the receptor for urokinase-type plasminogen activator on granulocytes and in plasma from patients with paroxysmal nocturnal hemoglobinuria.
Gao W; Wang Z; Bai X; Li Y; Ruan C
Int J Hematol; 2002 May; 75(4):434-9. PubMed ID: 12041678
[TBL] [Abstract][Full Text] [Related]
56. SuPAR, a potential inflammatory mediator in psoriasis pathogenesis.
Hamie L; Eid E; Abbas O; Safi R; Nammour T; Tamim H; Makki M; Stephan C; Hasbani D; Wehbe H; Ghaoui N; Hawa M; Nasser N; Eid A; Kibbi AG; Kurban M
Clin Exp Pharmacol Physiol; 2020 Oct; 47(10):1705-1712. PubMed ID: 32558953
[TBL] [Abstract][Full Text] [Related]
57. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
[TBL] [Abstract][Full Text] [Related]
58. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
59. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
60. Plasma Soluble Urokinase-Type Plasminogen Activator Receptor Level as a Predictor of the Severity of Community-Acquired Pneumonia.
Tsai PK; Tsao SM; Yang WE; Yeh CB; Wang HL; Yang SF
Int J Environ Res Public Health; 2019 Mar; 16(6):. PubMed ID: 30901954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
